Patents by Inventor Dirk Zboralski

Dirk Zboralski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
    Publication number: 20240115745
    Abstract: The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein Xaa1, Xaa2, Xaa3, Xaa4, Xaa5 and Xaa6 are each residues of an amino acid, Xaa7 is a residue of an amino thiol or an amino acid of formula, Yc is a cyclization element which is either present or absent, and the N-terminal modification group A is either a blocking group Abl or an amino acid Aaa.
    Type: Application
    Filed: January 7, 2022
    Publication date: April 11, 2024
    Inventors: Frank OSTERKAMP, Christian HAASE, Eberhard SCHNEIDER, Jonas PROKSCH, Dirk ZBORALSKI, Matthias PASCHKE, Christiane SMERLING, Ulrich REINEKE
  • COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
    Publication number: 20230212549
    Abstract: The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and Yc is a structure of formula (X)
    Type: Application
    Filed: January 7, 2022
    Publication date: July 6, 2023
    Applicant: 3B PHARMACEUTICALS GMBH
    Inventors: Frank OSTERKAMP, Dirk ZBORALSKI, Eberhard SCHNEIDER, Christian HAASE, Matthias PASCHKE, Aileen HÖHNE, Jan UNGEWIß, Christiane SMERLING, Ulrich REINEKE, Anne BREDENBECK, Jan Lennart von Hacht
  • Method of Modulating the Number and the Distribution of Tumor-Infiltrating Leukocytes in Tumors
    Publication number: 20230146246
    Abstract: The present invention is related to a molecule capable of inhibiting signaling between SDF-1 and CXCR4 and/or CXCR7, wherein the molecule is for use in a method of modulating the number and/or the spatial distribution of tumor-infiltrating leukocytes in a tumor and/or metastases.
    Type: Application
    Filed: June 19, 2022
    Publication date: May 11, 2023
    Applicant: NOXXON PHARMA AG
    Inventors: Axel Vater, Dirk Zboralski
  • COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
    Publication number: 20220315554
    Abstract: The present invention is related to a compound comprising a cyclic peptide of formula (I) and an N-terminal modification group A attached to Xaa1, wherein each and any one of Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6 and Xaa7 is a residue of an amino acid, and Yc is a structure of formula (X)
    Type: Application
    Filed: July 8, 2020
    Publication date: October 6, 2022
    Applicant: 3B PHARMACEUTICALS GMBH
    Inventors: Frank OSTERKAMP, Dirk ZBORALSKI, Eberhard SCHNEIDER, Christian HAASE, Matthias PASCHKE, Aileen HÖHNE, Jan UNGEWISS, Christiane SMERLING, Ulrich REINEKE, Anne BREDENBECK
  • COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF
    Publication number: 20220273831
    Abstract: The present invention is related to a compound comprising a cyclic peptide and a chelator, and its use.
    Type: Application
    Filed: July 8, 2020
    Publication date: September 1, 2022
    Inventors: Frank OSTERKAMP, Dirk ZBORALSKI, Eberhard SCHNEIDER, Christian HAASE, Matthias PASCHKE, Aileen HÖHNE, Jan UNGEWISS, Christiane SMERLING, Ulrich REINEKE, Anne BREDENBECK
  • Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
    Patent number: 11371045
    Abstract: The present invention is related to a molecule capable of inhibiting signaling between SDF-1 and CXCR4 and/or CXCR7, wherein the molecule is for use in a method of modulating the number and/or the spatial distribution of tumor-infiltrating leukocytes in a tumor and/or metastases.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: June 28, 2022
    Assignee: NOXXON Pharma AG
    Inventors: Axel Vater, Dirk Zboralski
  • CXCL8 Binding Nucleic Acids
    Publication number: 20210403913
    Abstract: The present invention is related to an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5?-GG A AGU ACGUGGA AAGCCRA(Xu)RAGUGUGUCCCG-3? [SEQ. ID. NO: 27], wherein Xu is U or absent.
    Type: Application
    Filed: November 12, 2019
    Publication date: December 30, 2021
    Applicant: Aptarion Biotech AG
    Inventors: Kai Hohlig, Axel Vater, Werner Purschke, Dirk Zboralski, Christian Maasch
  • Method of Modulating the Number and the Distribution of Tumor-Infiltrating Leukocytes in Tumors
    Publication number: 20200071701
    Abstract: The present invention is related to a molecule capable of inhibiting signaling between SDF-1 and CXCR4 and/or CXCR7, wherein the molecule is for use in a method of modulating the number and/or the spatial distribution of tumor-infiltrating leukocytes in a tumor and/or metastases.
    Type: Application
    Filed: April 18, 2017
    Publication date: March 5, 2020
    Applicant: NOXXON PHARMA AG
    Inventors: Axel Vater, Dirk Zboralski
  • SDF-1 binding nucleic acids and the use thereof in cancer treatment
    Patent number: 10093934
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Grant
    Filed: July 3, 2016
    Date of Patent: October 9, 2018
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
  • SDF-1 binding nucleic acids and the use thereof in cancer treatment
    Publication number: 20160355821
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Application
    Filed: July 3, 2016
    Publication date: December 8, 2016
    Applicant: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
  • SDF-1 binding nucleic acids and the use thereof in cancer treatment
    Patent number: 9387221
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: July 12, 2016
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
  • SDF-1 binding nucleic acids and the use thereof in cancer treatment
    Publication number: 20160095875
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Application
    Filed: November 20, 2015
    Publication date: April 7, 2016
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
  • SDF-1 Binding Nucleic Acids and the use Thereof in Cancer Treatment
    Publication number: 20130310442
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Application
    Filed: September 9, 2011
    Publication date: November 21, 2013
    Applicant: NOXXON PHARMA AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski